2026 Agenda

BREAKOUT DISCUSSION:
Sponsored by: Closing the MedTech Narrative Gap: Strategic Film as a Commercialization Engine 

VISUM explores the MedTech Narrative Gap—the disconnect between clinical innovation and market understanding. Through select film examples and a deeper case study featuring an emerging Series B MedTech disruptor, learn how cinematic films built around authentic clinical voices, real clinical environments, and 3D visualization align teams and accelerate understanding. These strategic assets strengthen clinician adoption, build investor confidence, and drive commercialization.

BREAKOUT DISCUSSION:
Sponsored by: Real-World Lessons from MedTech CEOs Who Have Navigated Funding, FDA Approval, and First-in-Human Trials

Experienced MedTech CEOs share lessons from navigating funding, FDA approval, and first-in-human trials, highlighting clinical strategy decisions that help de-risk development and accelerate company growth.

Sponsored by: SVB Healthcare Investment Landscape Overview

Explore 2026 medtech investment trends through SVB’s proprietary data, offering unrivaled market intelligence, M&A activity, and the evolving innovation landscape.

BREAKOUT DISCUSSION:
Sponsored by: Escalation Options for FDA Submissions

Learn how to manage your FDA submission review when things go sideways. This session covers practical escalation strategies for 510(k), De Novo, and PMA submissions: when to involve FDA management, how to communicate concerns effectively, and when informal versus formal appeals make sense—while preserving the relationship.

IN-PERSON ONLY BREAKOUT:
Sponsored by: LUNCHEON PRESENTATION: Capital-Raising and Strategic M&A Considerations for Growth-Stage Medtech Companies

Hear insights and learnings from industry professionals across the strategic and growth-stage medtech landscape. When is too early to engage with strategics? Who are the right groups to talk to? Is Corporate Venture Capital (CVC) still an option and what are they looking for? How should companies be thinking about financing in a world where timelines to exit are getting longer? Find answers to all of these questions and more as J.P. Morgan moderates a diverse panel on capital raising and strategic M&A considerations for growth-stage medtech companies.

INNOVATION SHOWCASE:
Sponsored by: Oncology Innovation: FDA Cleared, AI-Enabled, Separately Billable, Recurring Revenue

AIQ Solutions has commercialized an FDA-cleared, AI-enabled software medical device with a recurring revenue model. Targeting the most complex oncology patients — those with metastatic disease — AIQ's technology-enabled service improves treatment decisions while reducing expenditures on high-cost therapeutics. A separately billable CPT code, strong clinical data, and high payer return on investment are driving accelerating commercial demand.